Multivariate patterns of plasma biomarkers predict cognitive decline in Alzheimer’s disease, suggesting a new detection method.
Distinct plasma signatures reflect underlying AD pathways, supporting the use of blood-based biomarkers as cost-effective, noninvasive tools for early detection, disease monitoring, and individualized risk profiling.
No takes yet. Share an insight, caveat, or question.
Zamani et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: